60 degrees pharma announces type c meeting with fda to discuss development of tafenoquine for babesiosis, an emerging tick-borne disease

Type c meeting will be to discuss a proposed phase ii study of tafenoquine for treatment of babesiosis transmitted by ticks, babesiosis is a life-threatening parasitic disease increasing in frequency in the united states meeting with fda scheduled for january 15, 2024 washington, nov. 15, 2023 (globe newswire) -- 60 degrees pharmaceuticals, inc. (nasdaq: sxtp; sxtpw) (“60p” or the “company”), a pharmaceutical company focused on developing new medicines for infectious diseases, announced today that the u.s. food and drug administration (fda) has granted a type c meeting with the company to consult on the path forward in developing the tafenoquine regimen of arakoda® for a potential indication in treating hospitalized babesiosis patients. the meeting will take place on january 15, 2024.
SXTP Ratings Summary
SXTP Quant Ranking